GlycoMimetics Company Profile (NASDAQ:GLYC)

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLYC
  • CUSIP: N/A
  • Web:
  • Market Cap: $445.03 million
  • Outstanding Shares: 32,723,000
Average Prices:
  • 50 Day Moving Avg: $11.43
  • 200 Day Moving Avg: $9.19
  • 52 Week Range: $3.82 - $16.94
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.63
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18,500.00
  • Price / Sales: 24,055.83
  • Book Value: $3.53 per share
  • Price / Book: 3.85
  • EBIDTA: ($32,240,000.00)
  • Return on Equity: -44.33%
  • Return on Assets: -41.13%
  • Current Ratio: 21.99%
  • Quick Ratio: 21.99%
  • Average Volume: 470,042 shs.
  • Beta: 3.22
  • Short Ratio: 10.99

Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.07. View GlycoMimetics' Earnings History.

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

5 brokerages have issued 1-year target prices for GlycoMimetics' stock. Their predictions range from $9.00 to $21.00. On average, they expect GlycoMimetics' share price to reach $14.75 in the next year. View Analyst Ratings for GlycoMimetics.

What are analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (8/7/2017)
  • 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:

  • M. James E. Barrett Ph.D., Chairman of the Board
  • Rachel K. King, President, Chief Executive Officer, Founder, Director
  • Brian Hahn, Chief Financial Officer
  • John Magnani Ph.D., Chief Scientific Officer, Vice President - Research, Director
  • Helen M. Thackray M.D., Vice President - Clinical Development, Chief Medical Officer
  • Patricia S. Andrews, Director
  • Mark Alan Goldberg M.D., Director
  • Daniel M. Junius, Director
  • Scott Koenig M.D., Ph.D., Director
  • Timothy R. Pearson, Director

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (34.84%), Franklin Resources Inc. (7.54%), Jennison Associates LLC (6.47%), FMR LLC (6.10%), Vanguard Group Inc. (3.43%) and Redmile Group LLC (1.83%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., State Street Corp, Northern Trust Corp and Nationwide Fund Advisors. View Insider Buying and Selling for GlycoMimetics.

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Franklin Resources Inc., Redmile Group LLC, Janus Henderson Group PLC, Vanguard Group Inc., EAM Investors LLC and Broadfin Capital LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GlycoMimetics stock can currently be purchased for approximately $13.60.

MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.75 (8.46% upside)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/7/2017SunTrust Banks, Inc.Set Price TargetBuy$21.00LowView Rating Details
8/4/2017Stifel NicolausReiterated RatingBuy$13.00 -> $17.00LowView Rating Details
6/6/2017Jefferies Group LLCLower Price TargetBuy$16.00 -> $9.00HighView Rating Details
5/28/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for GlycoMimetics (NASDAQ:GLYC)
Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)
Earnings History by Quarter for GlycoMimetics (NASDAQ GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.37)($0.30)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
2017 EPS Consensus Estimate: ($1.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.38)($0.37)($0.38)
Q2 20172($0.40)($0.30)($0.35)
Q3 20172($0.43)($0.25)($0.34)
Q4 20172($0.44)($0.26)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ:GLYC)
Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 92.63%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Helen M ThackraySVPSell2,000$13.00$26,000.00View SEC Filing  
5/25/2017Helen M ThackraySVPSell2,000$15.57$31,140.00View SEC Filing  
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlycoMimetics (NASDAQ:GLYC)
Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
DateHeadline logoGlycoMimetics Inc (GLYC) Receives Consensus Rating of "Hold" from Brokerages - September 24 at 8:34 PM logoGlycoMimetics, Inc. (GLYC) SVP Sells $26,000.00 in Stock - September 18 at 8:10 PM logoGlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017 - September 11 at 7:37 PM logoZacks: Analysts Expect GlycoMimetics, Inc. (GLYC) to Announce -$0.29 EPS - September 11 at 10:38 AM logoCan GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions? - September 6 at 1:26 AM logoGlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference - September 6 at 1:26 AM logoGlycoMimetics, Inc. (GLYC) Upgraded to Hold by ValuEngine - September 3 at 10:56 AM logoGlycoMimetics, Inc. (GLYC) Given Consensus Recommendation of "Hold" by Analysts - August 30 at 8:36 PM logoGlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017 - August 26 at 3:21 AM logoGlycoMimetics, Inc. (GLYC) Rating Lowered to Sell at BidaskClub - August 20 at 12:36 PM logoQ3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust Banks - August 9 at 8:08 AM logoGlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017 - August 8 at 6:48 PM logoGlycoMimetics, Inc. (GLYC) Rating Lowered to Sell at Zacks Investment Research - August 8 at 12:34 AM logoGlycoMimetics, Inc. (GLYC) Posts Earnings Results, Beats Expectations By $0.07 EPS - August 5 at 9:56 PM logoGlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from Brokerages - August 5 at 8:56 PM logo Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS - August 5 at 12:44 PM logoStifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC) - August 5 at 11:34 AM logoGlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017 - August 1 at 7:41 PM logoGlycoMimetics, Inc. (GLYC) Downgraded to Hold at Zacks Investment Research - July 20 at 10:46 PM logoGlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017 - July 19 at 7:45 PM logoGlycoMimetics, Inc. (NASDAQ:GLYC) Upgraded to "Buy" at Zacks Investment Research - July 18 at 11:32 PM logoZacks: Analysts Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.38 EPS - July 14 at 11:14 AM logoGlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by Brokerages - July 11 at 8:50 PM logoFDA Issues an Approval Not Seen in Almost 20 Years - July 8 at 11:07 AM logoBRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271 - July 6 at 8:59 PM logoGlycoMimetics to Receive European Patent for GMI-1271 - July 6 at 8:59 PM logoAre Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? - June 30 at 3:22 PM logoZacks: Brokerages Expect GlycoMimetics, Inc. (GLYC) to Announce -$0.38 Earnings Per Share - June 20 at 8:18 AM logoGlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Brokerages - June 16 at 6:32 PM logoGlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors - June 12 at 6:16 PM logoShort Interest in GlycoMimetics Inc (GLYC) Rises By 248.2% - June 11 at 7:24 AM logoFY2017 EPS Estimates for GlycoMimetics Inc (GLYC) Boosted by Analyst - June 8 at 8:26 AM logoToday's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics - June 7 at 10:52 AM logoGlycoMimetics' (GLYC) Buy Rating Reiterated at Stifel Nicolaus - June 6 at 11:38 PM logoGlycoMimetics Inc (GLYC) Price Target Raised to $16.00 - June 6 at 9:18 AM logoBRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO - June 5 at 5:35 PM logoGlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference - June 5 at 5:35 PM logoGlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting - June 5 at 10:53 AM logoGlycoMimetics Inc (GLYC) Upgraded at ValuEngine - June 4 at 2:32 PM logoALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD - May 31 at 9:02 AM logoGlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271 - May 31 at 9:02 AM logoHelen M. Thackray Sells 2,000 Shares of GlycoMimetics Inc (GLYC) Stock - May 30 at 8:31 PM logoGlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - May 30 at 5:22 PM logoCowen and Company Reaffirms Outperform Rating for GlycoMimetics Inc (GLYC) - May 28 at 9:34 AM logoGlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AML - May 25 at 7:52 PM logoBRIEF-Glycomimetics Inc terminates sales agreement with Cowen and Company - May 25 at 7:52 PM logoGlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia - May 25 at 7:52 PM logoHere's Why GlycoMimetics Rose as Much as 21% Today - May 25 at 7:52 PM logoGlycoMimetics Announces Pricing of Public Offering of Common Stock - May 24 at 11:56 AM logoGlycoMimetics (GLYC) Plans 6M Share Common Stock Offering - May 23 at 5:07 PM



GlycoMimetics (GLYC) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff